Curriculum vitae

Prof Banie Boneschans
CV- B BONESCHANS
1 PERSONAL PARTICULARS
Boneschans, Barend
13 Krom Street, Potchefstroom, 2520, South Africa 1.1 Language skills
Afrikaans

1.2 Computer skills
Computer literate with excelent skills in the operation of the folowing software 1.3 Professional registration
Registered as a Pharmacist with the South African Pharmacy Council with 1.4 Current position at the University of North-west University (Potchefstroom
Head: Centre for Pharmaceutical and Biomedical Services 1.5 Career history
Employer
Position
Professor Pharmaceutics Head : Centre for Quality Assurance of Medicines (CENQAM) Head: WHO Collaborating Centre for Quality Assurance of Medicines Head: WHO Collaborating Centre for Quality Assurance of Medicines Project Manager: PEPFAR International Project Project Manager: PEPFAR International Project Leadership Academy of the North-west University
Completed training at the Leadership Academy from 2009-2011. The following Interpersonal Relationships, by Dr Jopie de Beer, Jopie van Rooyen and
Self-Knowledge and Interpersonal Relationships, by Dr Jopie de Beer,
Jopie van Rooyen and Partners SA (Pty) Ltd., June 2009. Practical application of values (understanding the value of values in
Practical application of values (inclination to use organisation’s values), by
Building Trustworthiness, by Jopie de Beer, Jopie van Rooyen and Partners
Customer relations, by Amanda Singleton, June 2009.
Teamwork, by Greyling Viljoen, June 2009.
Performance Orientation: Greyling Viljoen, June 2009.
Valuing Diversity (understanding the managerial sense of diversity) by
10. Valuing Diversity (making a habit of embracing diversity) by Vincent Maphai,
11. 360⁰ Managing Spectrum (influencing, negotiating and leading), by Willie
12. Competitive Intelligence by Mike Kuhn, Marie-Luce Muller & Van der Spuy
13. Cultivating a Learning Culture, by Makheni Motana, November 2009.
14. Thinking Strategically by Nick Binedell, November 2009.
15. Practising Innovation, by Pieter Geldenhuys, November 2009.
16. Thinking Strategically, by Clem Sunter, November 2009.
17. Managing both functional and dysfunctional conflict for optimal
outcomes, by Marty Ferreira, August 2010.
18. Establishing a value-driven work environment, by Anna-Rosa le Roux,
19. Learning to negotiate for win-win outcomes, by Manie Spoelstra, August
20. Developing an agility to know when and what to change, and the
competence to complete the change process, by Grant Freedman, August
21. The Art of Influencing, by Susan Wolmarans, Learning Link International,
22. How to influence someone beyond my authority, by Margie Viviers, August
23. How to be assertive, rather than passive or aggressive, by Makheni
24. How to resolve a serious conflict between two staff members, by Leigh

Leadership Academy: Multi-rater Competency Assessment, October 2009
Took part in a Multi-rater Competency Assessment in order to assess management competencies as perceived and rated by Superiors, Peers and Subordinates (11 raters). The following competencies were rated on a scale of 0 to 4: Utilising others (including understanding others) The average score over all the competecies as rated by the raters was 3.26 and equals the average score that was found for the whole of NWU management. Personality preferences as measured by Myers-Briggs Type Indicator (May
My personality preference is typed as Introversion, Sensing, Thinking, and Judging (ISTJ) and I’m therefore thorough, exacting, systemic hardworking and careful with detail. I enjoy working within organisations to improve procedures and processes, remaining loyal through both good and bad times. I prefer drawing energy from my own world of ideas, emotions and impressions and I’m taking in information through the five senses and noticing what is actual. The way I make decisions is by organising and structuring information to decide in a logical objective way. I have a preference for living a planned and organised life. My contribution to the organisation will be to: Get things done steadily and on schedule, concentrate on details and to be careful about managing them, have things at the right place at the right time, be counted on to honor commitments and follow through, and work within the organisation structure comfortably. 1. ACADEMIC AND PROFESSIONAL QUALIFICATIONS
2.1 School career
Name of Highschool: Vryburger Hoërskool, Primrose, Germiston 2.2 Tertiary qualifications
Qualification
Institution
Year obtained
Chemistry)*
*With Distinction
2. COURSES ATTEND
1. Analysis of Biological samples; Institute for Chromatography, Pretoria, July 1989. 2. Optimisation of LC using computer simulation, Institute or Chromatography, 3. Bioavailability and Bioequivalence Seminar, The Academy of Pharmaceutical 4. Project Management. Fred Pryor Seminars,Pryor Resources Inc.; Johannesburg, 5. Internal Quality Auditing course for Laboratories, Quality Advisory of Southern 6. Certificate in building, repairing and upgrading 486, pentium 1,2,3,4 and AMD Computer Machines, Computer College, Klerksdorp, July 2008. 3. PUBLICATIONS
4.1.1 Dissertation and thesis
Boneschans B. Dissolution properties and bioavailability of hydrochlorothiazide from different tablet formulations. M.Sc. Dissertation (Afrikaans). Potchefstroom University for CHE. 1982. Boneschans B. Bioavailability of tricyclic antidepressants. D.Sc. thesis (Afrikaans). Potchefstroom University for CHE. 1988. p.1-421. 4.1.2 Confidential research reports
Since 1987 research was focused on the investigation of quality related issues associated with medicines registered in South Africa as well as those used in the African Region. The results of these investigations are reported tot the South African Medicines Regulatory Authority and the World Health Organisation in the form of confidential research reports. The findings, as documented in the research reports, are peer reviewed by technical and academic experts associated with the expert committees of the various authorities. Due to the confidential nature of these reports reference to the reports are made by means of a code number or report name, as well as the date on which these reports were accepted by the various authorities. These reports are listed in ANNEXURE A.
Articles in scientific journals
4.2.1 Full length articles in international scientific journals
Boneschans B, Griesel RD and Koeleman HA. The induced electro- encephalographic changes of imipramine and the relation to it's single dose pharmacokinetics. Electroencephalography and Clinical Neurophysiology. Boneschans B, Koeleman HA and Griesel RD. Relationship between the pharmacokinetics and EEG changes after administration of a single dose of imipramine. South African Journal of Science. 1988. Vol. 84. p.432-434 Ackermann C, Cairncross C and Boneschans B. Transdermal absorption of digoxin: a new possible route of administration. South African Journal of Steyn HS, Koeleman HA and Boneschans B. Testing of bioequivalence of medicines using confidence intervals. South African Journal of Science. 1988. Koeleman HA, Van Zyl R, Steyn N, Boneschans B and Steyn HS. Influence of montmorillonite on the dissolution and bioavailability of phenytoin. Drug development and industrial pharmacy, 1990. Vol. 16(5), p.791-805. Pienaar EW, Boneschans B and Koelman HA. Rectal absorption of phenytoin in rabbits from polyethylene glycol suppositories. Drug Development and Industrial Pharmacy, 1991. Vol. 17(10), p.1397-1404. James R and Boneschans B. A reversed-phase method for the determination of niacinamide and riboflavin in dissolution samples of multivitamin-mineral combination capsules. Drug Development and Industrial Pharmacy, 1992. M Lovrek, B Zorc, B Boneschans and I Butula. Macromolecular prodrugs. VIII. Synthesis of polymer-gemfibrozil conjugates. International Journal of Pharmaceutics, 2000. Vol. 200(2000), p.59-66. M Lovrek, M Jadrijevic-Mladar Takac, B Zorc and B Boneschans. Gemfibrozil ester and amide derivatives – synthesis, spectroscopic characterisation and QSPR. Pharmazie. Vol 55 (2000) 11, p811-816. M Zovko, B Zorc, M Lovrek and B. Boneschans. Macromolecular prodrugs. IX. Synthesis of polymer-fenoprofen conjugates. International Journal of Boneschans, T van der Merwe, JC Wessels and B Zorc. Validation of the HPLCmethod for model determination of fenoprofen in onjugates with PHEA. Boneschans, T van der Merwe, J Breytenbach, B Zorc and M Zovko. Macromolecular prodrugs X. Kinetics of fenoprofen release from PHEA- fenoprofen conjugate. International Journal of Pharmaceutics, 2002. Vol 241 B Boneschans, JC Wessels, J van Staden, M Zovko, J Bergh. Piroxicam Benzoate-Synthesis, HPLC Determination and Hydrolysis. Drug Development and Industrial Pharmacy, 2003 Vol 29, Number 2, p155-160. 4.2.2 Full length articles in national scientific journals
Boneschans B and Koeleman HA. The influence of dissolution variables on the release of hydrochlorothiazide from different tablet formulations (Afrikaans). S.A. Journal of Pharmacy. April 1981. Vol. 48(4). p.175-178. Boneschans B. Dissolution testing plays key role in medicine analysis (English). S.A. Journal of Science. February 1998. Vol. 94. p. 93. 4.2.3 Abstracts published in national scientific journals
Boneschans B and Koeleman HA. The influence of dissolution variables on the release of hydrochlorothiazide from different tablet formulations (Afrikaans). S.A. Journal of Pharmacy. June 1980. Vol. 47(6), 1. Boneschans B and Koeleman HA. The comparison of dissolution data of different hydrochlorothiazide tablets (Afrikaans). S.A. Journal of Pharmacy. Boneschans B and Koeleman HA. The in vitro and in vivo correlation between the release and absorption of hydrochlorothiazide from tablets (Afrikaans). S.A. Journal of Pharmacy. 1985. Vol. 53(3), 2. Boneschans B, Koeleman HA and Griesel RD. The relation between mood and imipramine concentration in the blood of Volunteers (Afrikaans). S.A. Journal of Pharmacy. 1986. Vol. 53(3), 76. Boneschans B, Griesel RD and Koeleman HA. The relation between imipramine induced EEG changes and the single dose kinetics of imipramine (Afrikaans). S.A. Journal of Pharmacy. 1987. Vol. 54(3), 1. Koeleman HA and Boneschans B. The bioavailability of chlorpropamide (Afrikaans). S.A. Journal of Pharmacy. June 1980. Vol. 47(6), 245. Koeleman HA, Steyn HS, Boneschans B and Du Preez SH. The comparison of compartmental and noncompartmental approach for determining bio- equivalency (Afrikaans). S.A. Journal of Pharmacy. 1986. Vol. 53(3), 69. Du Preez SH, Boneschans B and Koeleman HA. The influence of the type of meal on the bioavailability of methyltestosterone from tablets (Afrikaans). S.A. Journal of Pharmacy. 1986. Vol. 53(3), 69. Steyn HS, Koeleman HA and Boneschans B. The comparison of different statistical methods for testing bio-equivalencey in medicines with a narrow therapeutic index. S.A. Journal of Pharmacy. 1986. Vol. 53(3), 69. 10. Cairncross C, Ackermann C and Boneschans B. The percutaneous absorption of digoxin in vivo. S.A. Journal of Pharmacy. 1986. Vol. 53(3), 74. 11. Steyn HS and Koeleman HA. The use of simulated blood data to determine the influence between compartmental and noncompartmental bioavailability parameters (Afrikaans). S.A. Journal of Pharmacy. 1987. Vol. 54(3), 78. 12. Van Zyl R, Koeleman HA and Boneschans B. The influence of montmorillonite on the dissolution rate of phenytoin (Afrikaans). S.A. Journal of Pharmacy. 13. Boneschans B, Griesel RD and Koeleman HA. The induced electro- encephalographic changes of imipramine and the relation to its single dose pharmacokinetics. S.A. Journal of Pharmacy. 1987. Vol. 53(3), 78. 14. Boneschans B. Animal usage in medicine testing. S.A. Association for Laboratory Animal Science, Congress proceedings. p. 18, 30 September Other publications
Boneschans B. A practical guide for dispensing (Afrikaans). Wesvalia, Potchefstroom. 1984. 121p. ISBN 086809062X. Boneschans B and Malan MM. Pharmaceutical unit processes (Afrikaans). Wesvalia, Potchefstroom. 1983. 100p. ISBN 0868090166. Boneschans B. A practical guide for dispensing - Part II (Afrikaans). 1985. Boneschans B. Capsules (Afrikaans). Wesvalia, Potchefstroom. 1980. 41p. 4. ACADEMIC ACTIVITY
External examiner for the following
Du Plessis J. The stability of emulsions in parenteral nutrition mixtures (Afrikaans). M.Sc. dissertation. Potchefstroom Univeresity for CHE. 1986. Everson A. A comparative study of closed and open diffusion cell systems for percutaneous absorption studies (Afrikaans). M.Sc. dissertation. Keeve E. The percutaneous absorption of oxytetracycline through cattle skin (Afrikaans). M.Sc. dissertation. Potchefstroom University for CHE. 1988. Marais AF. The influence of formulation and manufacturing variable on the properties of furosemide tablets (Afrikaans). M.Sc. dissertation. Potchefstroom Wang C. Correlation of in vivo in vitro availability data of diclofenac sodium in modified release dosage forms. M.Pharm dissertation. University of Pretoria. Leathern, L. Computerised medicine registration - a study in South Africa. Meyer, G.E. Die invloed van generiese reseptering op die winsgewendheid van apteke in die Vrystaatse Goudveld, Potchefstroom University, 1996. De Jager, M. Quality specifications for the antimalarial compound lumefantrine and products thereof. PhD thesis. North-west University: Potchefstroom Joubert, R. Hypertension treatment in a section of the prescribed management benefit market in South Africa. PhD thesis. North-west University: Potchefstroom campus, Potchefstroom, 2012. Research contracts
Contract research was done in accordance of the provisions of a contract between the former Faculty of Pharmacy and the Medicines Control Council. The research was directed towards solving problems regarding the pharmaceutical availability and/or the bioavailability of different formulations on the South African market. Current research is in accordance with the terms of reference of the WHO Collaborating Centre and is mainly focused on the quality assessment of anti- malarials and anti-tuberculosis medicine available in the African Region. Academic research
Own academic research is under taken in the following fields: Development of in vitro dissolution models for non-sterile anti-inflammatory drug Teaching experience
Teaching Pharmaceutics to undergraduates for the period 1980 to 1990 on subjects Biopharmaceutics, Solid dosage forms, Pharmaceutical unit processes and Training courses
Training courses developed and presented for and on behalf of Health Science
Academy (PTY) Ltd:
• Analytical Procedure Validation • Pharmaceutical Process Validation • Dissolution Testing: Back to Basics Training courses developed and presented on behalf of WHO Regional Office for
• Pharmaceutical Analyst Training • Fundamentals of Validation • Good Laboratory and Analytical Practices • Good Manufacturing Practice • Managing the Analytical Laboratory • Process Validation Study guidance to post graduate students
Leader for the following students
Pienaar EW. The rectal absorption of phenytoin in animals (Afrikaans). M.Sc. Potchefstroom University for CHE. 1988. Coetzee M. The polymerization of aminopenicillins in liquid dosage forms (Afrikaans). M.Sc. Potchefstroom University for CHE. 1991. Wrigley G. Computer validation in the pharmacuetical industry: A new Van der Merwe T. Validation of the HPLC method for model determination of fenoprofen in conjugates with PHEA. M.Sc Pharm. 2000. Co leader for the following students
Preston A. Carbamazepine - the formulation of a liquid oral dosage form with prolonged release characteristics and the in vivo evaluation thereof. M.Sc. University of the North. Starting date 1990. Jordaan B. The comparison of the bioavailability and EEG parameters of Steyn M. The involvement of the hospitalpharmacist in stoma patient care. Cairncross C. The percutaneous absorption of digoxin. Du Preez SH. The influence of food on the bioavailability of methyl testosterone from tablets (Afrikaans). M.Sc. Potchefstroom University for Van Zyl R. The in vitro and in vivo availability of phenytoin from montmorillonite reaction mixtures (Afrikaans). M.Sc. Potchefstroom Steyn N. A comparison of compartmental and no compartmental methods for the testing of bio-equivalency (Afrikaans). Potchefstroom University for Wessels JC. The influence of various types of breakfast on the absorption of paracetamol among Tswanas. M.Sc. Potchefstroom University for CHE. Smith, S.C. 1996. Die in vitro/in vivo korrelasie van die farmaseutiese beskikbaarheid uit setpille met behulp van die deurvloei-dissolusie sisteem. 5. MEMBER OF SOCIETIES, COMMITTEES AND BOARDS
Member of the committee for Professional Services, School of Pharmacy, Member of the S.A. Academy for Pharmaceutical Sciences. Member of the Official Laboratory and Medicines Control Services, Section of the International Pharmaceutical Federation. 6. GRANTS
Grant for overseas visit. Committee for International Relations, Potchefstroom Grant for overseas visit. Foundation for Pharmaceutical Education. R970.00. Research grant. Pharmaceutical Manufacturers' Foundation. R2 500.00. 1987. Research grant. Noristan. R1 000.00. 1987. Merit grant. International Federation of Societies for Electroencephalography and Clinical Neurophysiology. R1 000.00. 1987. Salusa grant. Potchefstroom University for CHE. R1 000.00. 1987. Research grant under the Verka programme. Potchefstroom University for CHE. 7. CONTRACT RESEARCH / SERVICES
Contract with the Medicines Control Council (1988-1992) for R1 650 000 Contract with the Medicines Control Council (1992-1994) for R790 000 Contract with the Medicines Control Council (1994-1996) for R956 000 Contract with the Medicines Control Council (1996-1998) for R223 800 Contract with World Health Organisation (2002-2003) for R220 000 Contract with American Government (PEPFAR Project) (2005-2013) 8. VISITS OVERSEAS AND PROFESSIONAL SERVICES
Pharmaceutical and clinical research divisions at Sandoz, in Basel, Switzerland. Retail pharmacies in England, Spain, Greece, France and Switzerland. May- Visit to the Analytical Section at Ciba in Basel, Switzerland, 21-22 June 1994. Attending the Bio-International '94 Congress in Munich, Germany, 16-18 June Study tour visiting Official Medicines Control Laboratories in Scotland (Medicines Testing Laboratory), Germany (Zentrallaboratorium), The Netherlands (Rigo), Switzerland (WHO Headquarters). 20-31 March 1996. Attending the 57th International Congress of FIP in Vancouver, Canada, 31 Attending the 58th International Congress of FIP in The Hague, The Netherlands, 30 August - 4 September 1998. Visiting the University of Zagreb, Croatia, 6 September - 10 September 1998. 9. CONTRIBUTIONS AT NATIONAL CONFERENCES
Boneschans B and Koeleman HA. The influence of dissolution variables on the release of different hydrochlorothiazide formulations (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Grahamstown. 1980. Boneschans B and Koeleman HA. The comparison of dissolution data for different hydrochlorothiazide tablets (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Durban. 1981. Boneschans B and Koeleman HA. The in vitro and in vivo correlation of the release and absorption of hydrochlorothiazide from tablets (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Port Elizabeth. Boneschans B, Koeleman HA and Griesel RD. Electro-encephalography as a method for determining the bioavailability of antidepressants (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Pretoria. 1985. Boneschans B, Griesel RD and Koeleman HA. The relation between mood and the imipramine concentration in the blood of test subjects (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Cape Town. 1986. Koeleman HA and Boneschans B. The bioavailability of chlopropamide (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Koeleman HA, Steyn HS, Boneschans B and Du Preez SH. The comparison of compartmental and noncompartmental approach to bioequivalence testing (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Cape Du Preez SH, Boneschans B and Koeleman HA. The influence of the type of meal on the bioavailability of methyl testosterone from tablets (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Cape Town. 1986. Steyn HS, Koeleman HA and Boneschans B. The comparison of different statistical methods for the testing of bio-equivalence of medicines with a narrow therapeutic index (Afrikaans). Conference of the Academy for Pharmaceutical 10. Cairncross C, Ackermann C and Boneschans B. The percutaneous absorption of digoxin in vivo. Conference of the Academy for Pharmaceutical Sciences, 11. Steyn HS and Koeleman HA. The use of simulated blood data to calculate the influence between compartmental and noncompartmental bioavailability parameters (Afrikaans). Conference of the Academy for Pharmaceutical 12. Van Zyl R, Koeleman HA and Boneschans B. The influence of montmorillonite on the dissolution rate of phenytoin (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Grahamstown. 1987. 13. Boneschans B, Griesel RD and Koeleman HA. The induced electro- encephalographic changes of imipramine and the relation to its single dose pharmacokinetics. Conference of the Academy for Pharmaceutical Sciences, 14. Coetzee M, Boneschans B and Van Wyk CJ. The polymerization of aminopenicillins in liquid dosage forms (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Potchefstroom. 1991. 15. Wessels JC, Koeleman HA and Boneschans B. The influence of various types of breakfast on the absorption of paracetamol in Tswanas. Conference of the Academy of Pharmaceutical Science, Johannesburg, 1990. 16. Steyn HS and Boneschans B. Using confidence intervals for testing equivalency in dissolution data (Afrikaans). Conference of the Academy for Pharmaceutical Sciences, Johannesburg. 1990. 17. Buys GM, Boneschans B, Pienaar EW and Lötter AP. Differential scanning calorimetry (DSC) screening of the compatibility between pyrimethamine, chloroquin and tablet excipients. Conference of the Academy of Pharmaceutical 18. Jordaan B, Koeleman HA, Boneschans B, Steyn HS, Ellis SM, Snyckers F and Griesel RD. The bioavailability of phenytoin from three dosage forms after single and multidosing. Conference of the Academy of Pharmaceutical 19. Boneschans B. Generation and presentation of dissolution data. Drug registration symposium, CSIR Conference Centre, Pretoria. 1992. 20. Smith, S.C., Van Wyk, C.J., Boneschans, B. & Wessels, J.C. The in vitro/in vivo correlation of the pharmaceutical availability of rectal dosage forms using the flow-through dissolution method. (Poster). The First Conference on Pharmaceutical and Pharmacological Sciences. Eskom Conference and Exhibition Centre, Midrand, Gauteng, South Africa. 22-25 September 1996. 10. CONTRIBUTIONS AT INTERNATIONAL CONFERENCES
Boneschans B en Griesel RD. Induced electroencephalographic changes of imipramine and the relation to its pharmacokinetic parameters. 8th International Conference of Miography and Related Neurophysiology, Sorento, Italy, 1987. Boneschans B, Koeleman HA en Steyn HS. The unexpected absorption characteristics of imipramine from an oral solution. Third International Conference on Drug Absorption, Edinburgh, 1988. Koeleman HA, Van Zyl R, Boneschans B, Steyn N en Steyn HS. The influence of montmorillonite on the absorption of phenytoin. Third International Conference on Drug Absorption, Edinburgh, 1988. Koeleman HA, Pienaar EW en Boneschans B. The influence of the suppository base on the dissolution and absorption of phenytoin from suppositories. 5th International Pharmaceutical Technology Symposium, Ankara, Sept. 1990. Wessels JC, Koeleman HA, Boneschans B en Steyn HS. The influence of various types of breakfast on the absorption of paracetamol in Tswanas. 5th International Pharmaceutical Technology Symposium, Ankara, Sept. 1990. Pienaar EW, Boneschans B and Koeleman HA. The bioavailability of phenytoin suppositories. Conference of the Academy for Pharmaceutical Sciences, Sun Steyn N, Koeleman HA, Steyn HS and Boneschans B. Comparing compartmental and noncompartmental methods for bio-equivalence testing. Conference of the Academy for Pharmaceutical Sciences, Sun City, Boneschans B, Koeleman HA, Steyn N and Steyn HS. Compartmental and noncompartmental parameters for amitriptyline after intravenous and oral administration. Conference of the Academy of Pharmaceutical Science, Sun Koeleman HA, Steyn HS, Steyn N and Boneschans B. Comparison of compartmental and noncompartmental approach for bioequivalence testing of three different drugs. Conference of the Academy of Pharmaceutical Science, 10. Pienaar EW, Kriek NJP, Boneschans B, Koeleman HA and van der Nest DG. The effect of phenytoin and PEG on the rectal mucosa of the rat. Conference of the Academy of Pharmaceutical Science, Sun City, Bophuthatswana, 1989. 11. Boneschans B, Zorc B. Counterfeit medicines in developing countries: The African Experience. 2nd Croation Congress on Pharmacy, Cavtat, Croatia, May 12. Boneschans B, Van der Merwe T, Wessels A, Zorc B. Validation of a HPLC method for the determination of a fenoprofen conjugate. 10th International conference on Pharmaceutical Technology, Florence, April 2002. 11. SPECIAL ASSIGNMENTS
Acting as WHO consultant for establishing First Stage Quality Control Laboratories in Eritrea and Swaziland (1995-1996). Acting as WHO consultant for reviewing the pharmaceutical sector in 12. HOBBIES AND SPORT
13. LIFE’S MISSION
To utilise God-given talents and opportunities to the honour of God
and the benefit of all people.
ANNEXURE A
REFERENCES TO CONFIDENTIAL REPORTS
Report nr. Petogen injection, March 1995, 6p. Report, Analise van petogen inspuiting, (B/N's S41304 en 1439), March 1995, 1p. Report, IIternasionale Furosemied Projek, no. 130695, 4p. Report, Puresis tablette, no. 140695, 3p. Report, Gencetamol tablette, no. 140895A, 5p. Report, Eritromisienestolaatprodukte, no. 310895, 1p. Report, Siklisienhidrochloriedtablette, no. 180995A, 4p. Report, Carbatol-200 tablets, no. 060795, 3p. Report, Carbatol-200 tablets, no. 210995A, 5p. Report, Warfarin Natrium 5 mg - Lennon tablette, no. 210995B, 4p. Report, Painrite SA kapsules, no. 290995, 4p. Report, Dino-Cod tablette, no. 301095. 3p. Report, Adco-Cimetidine 200 mg tablette, no. 201195, 3p. Report, Daramal tablette, no. 281195, 4p. Report, Multinational Theophylline Study, 3p. Report, Multinational Theophylline Study, Februarie 1996, 6p. Report 01/96CAF, Caffeine in Red Eagle, Sep. 1996, 3p. Report 02/96IND(13/96), Indapamide in Hydro-Less tablets, Oct. 1996, 3p. 100. Report 03/96ZIN(01/96), Zinc and Castor Oil Cream, Oct. 1996, 2p. 101. Report 04/96ZIN(05/96), Zinc Ointment B.P., Oct 1996, 2p. 102. Report 05/96MET(04/96), Methyl Salicilate content of Wintergreen ointment, Oct 103. Report 01/97MUT(05/96), Carbonates - Muti we wabantwana, Jan. 1997, 5p. 104. Report 02/97LIO(05/96), Sodium Bicarbonate, Aloe, Total Solids, Jan. 1997, 1p. 105. Report 03/97MEB(08/96), Mebendazole in VERMOX tablets, Jan. 1997, 4p. 106. Report 04/97BEV(12/96), BEVISPAS tablets, Jan. 1997, 7p. 107. Report 970404, Oxytetracycline in O-4 Cycline 250mg capsules, Mrt 1997, 4p. 108. Report 970405, Oxytetracycline in Be-Oxytet 250mg capsules, Mrt 1997, 1p. 109. Report 970401, Tetracycline in Gammatet 250mg capsules, Apr. 1997, 3p. 110. Report 970304, Cloxacillin in Cloxin 500mg capsules, Apr. 1997, 4p. 111. Report 970308, Bu-Tone Cream, Apr. 1997, 3p. 112. Report 970402, Minocycline in Cyclimycin 100mg capsules, Apr. 1997, 2p. 113. Report 970403, Minocycline in Minomycin 100mg capsules, Apr. 1997, 3p. 114. Summary report on Products of African Medicines, May 1997, p5. 115. Summary report on the quality screening of tetracycline products, May 1997, p4. 116. Report nr. 970603, Erythromycin in Estomycin 250S suspension, June 1997, p2. 117. Report nr. 970602, Erythromycin in Purmycin 125 suspension, June 1997, p2. 118. Report nr. 970601, Erythromycin in Pumycin 250mg capsules, June 1997, p2. 119. Report nr. 970209, Ampicillin in PENBRITIN S syrup, June 1997, p2. 120. Report nr. 970207, Ampicillin in HEXACILLIN 250mg capsules, July 1997, p2. 121. Report nr. 970204, Ampicillin in AMPISALT 250mg capsules, June 1997, p2. 122. Report nr 970301, Amoxycillin in UNIMOX 500mg capsules, June 1997, p2. 123. Report nr. 970302, Amozycillin in UNIMOX suspension, June 1997, p2. 124. Report nr. 970303, Phenoxymethylpenicillin in INCIL VK suspension, June 1997, 125. Report nr. 970304, Cloxacillin in CLOXIN 500mg capsules, April 1997, p2. 126. Report nr. 970305, Amoxycillin in MOXAN suspension, June 1997, p2. 127. Report nr. 970306, Amoxycillin in AUGMENTIN suspension, June 1997, p2. 128. Report nr. 970307, Amoxycillin in AUGMENTATIN 375 tablets, July 1997, p2. 129. Report nr. 970508, Theophylline in ALCOPHYLLIN mixture, September 1997, p2. 130. Report nr. 970604, Erythromycin in ILOSONE 250mg capsules, September 1997, 131. Report nr. 970606, Erythromycin in ADCO-ERYTHROMYCIN 250mg capsules, 132. Report nr. 970801, Pyrazinamide in ROZIDE 500mg tablets, September 1997, p2. 133. Report nr. 970802, Ethionamide in ETHATYL 250mg tablets, September 1997, p2. 134. Report nr. 970803, Isoniazid in NORSTAN-ISONIAZID 100mg tablets, September 135. Report nr. 970806, Ethionamide in ETHATYL 250mg tablets, October 1997, p2. 136. Report nr. 970901, Metronidazole in FLAGYL 500mg suppositories, September 137. Report nr. 970902, Metronidazole in METROSTAT 400mg tablets, October 1997, 138. Report nr. 971103, Saquinavir in INVIRASE 200mg capsules, December 1997, p2. 139. Report nr. 971104, Indinacir in CRIXIVAN 400mg capsules, December 1997, p2. 140. Report nr. 971105, Zidovudine in RETROVIR 100mg capsules, December 1997, p2. 141. Report nr. 971102, ceftivuten in CEDAX 400mg capsules, February 1998. 142. Report nr. AH970810, NEOLYTE, Batch 10621, March 1998, p2. 143. Report nr. 970212, Piperacillin monohydrate in PIPRIL 4g, January 1998, p2. 144. Report nr. 971101, Cefachlor in CECLOR 125P oral suspension, October 1997, p2. 145. Report nr. 980701, Chlorpropamide in DIABETIX 250gm tablets, May 1998, p2. 146. Report nr. 970509, Thophylline in UNIPHYL 400mg tablets, January 1998, p2. 147. Report nr. 980501, Lorazepam in ATIVAN 2,5mg tablets, April 1998, p2. 148. Report nr. 970511, Theophylline in UNIDUR 400mg SR tablets, June 1998, p2. 149. Report nr. 980502, Diazepam in Benzopin 2mg tablets, June 1998, p2. 150. Report nr. 970209, Ampicillin in PENBRITIN S (125mg/5ml) SYRUP, June 1997, 151. Report nr. 970210, Ampicillin in BE-AMPICIL (125mg/5ml) SUSPENSION, July 152. Report nr. 971111, Cephradine in CEFRIL 125 suspension, July 1998, p2. 153. Report nr. 970903, Metronidazole in BERAZOLE 200mg tablets, July 1998, p2. 154. Report nr. 980302, Hydralazine HCI in APRESOLINE 25 tablets, July 1998, p2. 155. Report nr. 980202, Nifedipine in CARDILAT 10mg capsules, July 1998, p2. 156. Report nr. 980601, Allopurinol in REDURATE 150mg capsules, August 1998, p2. 157. Report nr. 980702, Gliclazide in DIAMICRON 80mg tablets, October 1998, p2. 158. Report nr. 980500, Amoxycillin (125mg/5ml) in AMOXIL oral suspension - ERITRE, 159. Report nr. 980800, REGIBLOC Spinal with Dextrose 4ml - INTRAMED, August 160. Report nr. 980103, Atenolol in APO-ATENOLOL 50mg tablets, October 1998, p2. 161. Report nr. 980700, Methyldopa in METHYLDOPA 250mg tablets, Norethisterone, 162. Report nr. 970206, Ampicillin in PETERCILLIN S-125 SUSPENSION (two batches), 163. Report nr. 970210, Ampicillin in BE-AMPICIL Suspension (different batches), July 164. Report nr. 970205, Ampicillin in PETERCILLIN 500mg capsules (two batches), June 165. Report nr. 970211, Ampicillin in BE-AMPICIL 250mg capsules (two batches), 166. Report nr. 970510, Theophylline in MYCROPHYLLIN 250mg SR capsules, May 167. Report nr. 971001, Quinine dihydrochloride in ADCO-QUININE 168. Report nr. 971002, Chloroquine sulphate in PLASMAQUINE 200mg capsules, May 169. Report nr. 970804, Rifampicin in RIFCIN 150mg capsules, June 1998, p2. 170. Report nr. 970807, Rifabutina in MYCOBUTIN capsules, June 1998, p2. 171. Report nr. 980401, Carbamazepine in TEGRETOL S 100mg/5ml suspension, July 172. Report nr. 980102, Atenolol in ATENOBLOK 50, 100 tablets, July 1998, p2. 173. Report nr. 970607, Erythromycin in EMU-V 250mg tablets, August 1998, p2. 174. Report nr. 980801, Mebendazole in CIPEX 100mg/5ml suspension, October 1998, 175. Report nr. 980301, Enalappril maleate in RENITEC 5 mg tablets, September 1998, 176. Report nr. 980602, Probenecid in BENEMID 500mg tablets, Augustus 1998, p2. 177. Report nr. 981000-1, Indomethacin in INDOMETHACIN 25mg capsules, October 178. Report nr. 970605, Erythromycin stearate in ETHIMYCIN 250mg capsules, July 179. Report nr. 981101, Tretinoin in DERMA-T TOPICAL GEL, December 1998. 180. Report nr. 981000-3, Co-trimoxazole tablets 400mgS+80mgT, November 1998. 181. Report nr. 980504, Temazzepam in T-PAM 10mg tablets, December 1998. 182. Report nr. 980802, Praziquantel in BILTRICIDE 600mg tablets, December 1998. 183. Report nr. 980104, Atenolol in NORTON-ATENOLOL 50mg tablets, November 184. Report nr. 981000-2, Tetracycline HCI in TETRACYCLINE HCI 250mg capsules, 185. Report nr. AH980201, CEPHRADINE in CEFRIL 125mg/ml powder for suspension, 186. Report nr. 990101, SULPHAMETOXAZOLE and TRIMETOPRIM in TRIMZOL 187. Report nr. 990102A-F, Identification of composition, Eden thin, shape, toner, melatonin, neurest, chromium, March 1999. 188. ERYTHROMYCIN LIQUID AND SOLID DOSAGE FORMS, February 1999. 189. Summary report on products of African Medicines, June 1997. 190. Summary report on quality screening of Tetracycline Products, May 1997. 191. Report nr. 990103, Macaine HCI 0,5% spinale injection with dextrose, May 1999. 192. Report nr. 980203, Nifedipine in APO-NIFED 5mg capsules, September 1999. 193. Report nr. 980204, Nifedipine in ADALAT 5mg tablets, September 1999. 194. Report nr. 990701, Indapamide in NATRILIX 2,5mg tablets, September 1999. 195. Report nr. 990702, Hydrochlorothiazide in DICHLOTRIDE *25 tablets, September 196. Report nr. 990603, Cafeine and ephedrine HCI in slimming dragees, September 197. Report nr. 991018/3, Prazinamide in PYRAZINAMIDE 500mg tablets, October 198. Report nr. 991018/4, Chloroquine phosphat tablets 241,9mg, November 1999. 199. Report nr. 991018/7, Ethambutol in ETHAMBUTOL 400mg tablets, November 200. Report nr. 991018/8, Cloxacillin sodium in CLOXACILLIN 250mg capsules, 201. Report nr. 991018/9, Phenobarbitone in PHENOBARBITONE 30mg tablets, 202. Report nr. 991018/11, Carbamazepine in CARBAMAZEPINE 200mg tablets, 203. Report nr. 991018/1, Rifampicin/Isoniazide 300mg/150mg tablet, December 1999. 204. Report nr. 991018/6, Cafaclor in CEFACLOR VERCEF (MR) 375mg tablets, 205. Report nr. 991018/5, Penicillin V in PENICILLIN V 250mg tablets, December 1999. 206. Report nr. 991018/2, Rifampicin/Isoniazide 150mg/100mg tablet, December 1999. 207. Report nr. 991001, Hydroquinone and Steroids in various creams and lotions, 208. Report nr. 991200.1, Identification of Hydroquinone in Topical products, December 209. Report nr. 991018/12, Erythromycin 250mg BP tablets, February 2000. 210. Report nr. 20000401, Theophylline 30mg/ml rectal solution, April 2000. 211. Report nr. 20000301, Comparative investigation of Fluoxetine Hydrochloride 212. Report nr. 20000402, Pharmacopoeial identification of Hydroquinone in Topical 213. Report nr. 20000601, Identification of Hydroquinone in Topical Lotions, June 2000. 214. Report nr. 20000501, Gentili Humidity Regulator Fluid, June 2000. 215. Report nr. 20000502, Intramed Neolyte injection/Infusion, July 2000. 216. Report nr. 20000805, Sulfametoxazole and Trimethoprim in Cotrimox, August 217. Report nr. 20000803, Diazepam in Diazepam 5mg tablets, August 2000. 218. Report nr. 20000711, Sodium Lactate, August 2000. 219. Report nr. 20000701, Bromhexine hydrochloride in various products, August 2000. 220. Report nr. 20000706, Clotrimazole in CLOSCRIPT VAGINAL, Sept 2000. 221. Report nr. 20000801, Identification of HYDROQUINONE IN TOP CREAM, August 222. Report nr. 20000802, Calcium content of SABAX dialysis mixture 223. Report nr. 20000807, Hydrogen peroxide in HYDROGEN PEROXIDE 3% 224. Report nr. 20000810, Manganese sulphate in MANGANESE SULPHATE injection, 225. Report nr. 20000811, Potassium chloride in POTASSIUM CHLORIDE 15% (for 226. Report nr. 20000813, PYRIDOXINEHCI (B6) INJECTION, August 2000. 227. Report nr. 20000815, Panthotenic acid (B5), August 2000. 228. Report nr. 20000901, Opipraml dithydrochloride in various products, Sept 2000. 229. Report nr. 20000902, Sodium Lactate Solution 50%, Sept 2000. 230. Report nr. 20000903, Melperone HCI in various products, Sept 2000. 231. Report nr. 20001201, FLUCONAZOLE in Biozole 200mg capsules, December 232. Report nr. 20010101, Identification of hydroquinone in RICO complexion cream, 233. Report nr. 20010201, LCMS proficiencyprogramme 2001, February 2001. 234. Report nr. 20010101, Identification of hydroquinon in RICO cemplexion cream, 235. Reprot nr. 20010201, LCMS proficiency programme 2001, February 2001. 236. Report nr. 20010302, Identification of hydroquinone in TURA FAST GEL, March 237. Report nr, 20010201, LCMS proficiency programme 2001, February 2001. 238. Report nr, 20010302, Identification of Hydroquinone in Tura Fast Gel, March 2001. 239. Report nr, 20010303, Stability analytical report for Daraprim 25mg tablets 240. Report nr, 20010304, Stability analytical report for Daraprim 25mg tablets. 241. Report nr, 20010305, Stability analytical report for Daraprim 25mg tablets 242. Report nr, 20010306, Stability analytical report for Valoid 50mg tablets 243. Report nr, 20010307, Stability analytical report for Valoid 50mg tablets 244. Report nr, 20010308, Stability analytical report for Valoid 50mg tablets 245. Report nr, 20010501, Fluconazole in Biozole 200mg capsules 250. QUALITY SCREENING OF ANTIMALARIAL PRODUCTS IN SIX AFRICAN COUNTRIES, Summary Report Antimalarial products, November 2002.

Source: http://www.nwuexperts.co.za/files/cvprofba1374674048_986.pdf